Navigation Links
Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
Date:8/31/2011

ZURICH, Switzerland, September 1, 2011 /PRNewswire/ --

Study Assessing the Safety and Efficacy of KUR-211 Expected to Report in mid 2012

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed recruitment in a Phase IIb clinical trial designed to investigate KUR-211 (Viz.I-020201) in the treatment of diabetic foot ulcers.

This Phase IIb clinical trial is a randomised, multi-center, controlled, parallel group dose-finding study to evaluate the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcers. KUR-211 is a bioactive therapy intended for topical treatment of diabetic foot ulcers, stimulating the granulation tissue formation, that aids wound closure. The study evaluates the effects of KUR-211 applied twice a week for maximum 16 weeks in addition to standard of care versus standard of care (SOC) alone.

KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and is applied to the wound as a foam. The innovative Kuros "TG-hook" technology enables the PDGF to be retained at the site for local exposure to migrating cells and for sustained delivery of PDGF on enzymatic cleavage of the matrix. It is believed that this novel approach may improve the frequency and speed of healing.

A total of 211 patients have been randomized and treated in over 27 centers across Europe including Russia. The primary endpoint of this study is percentage reduction in ulcer surface area after 4 weeks of treatment when compared to SOC alone.  Patients are followed for 7 months following initial treatment. Kuros is expecting to report the outcome of this study around the middle of 2012.

Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: "We are very pleased t
'/>"/>

SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
6. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
9. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
10. Roche completes acquisition of ARIUS
11. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK CITY ... -- As a leading provider of market research reports and ... Worldwide, LLC, indicating that 2015 will be a year of ... For executives operating a stem cell company or cord ... difficult task. You must analyze market conditions, predict industry trends, ...
(Date:4/1/2015)... 2015 National recruitment firm Slone ... Brad Allen as Head of Sales at Optimal Medicine, ... market. , Allen brings over 20 years experience ... a number of companies including Dell Services Healthcare, Medsphere ... were a perfect fit for accomplishing the goals Optimal ...
(Date:3/31/2015)... March 31, 2015  Biotest Pharmaceuticals Corporation (BPC), a ... announce the addition of its newest plasma collection center ... Conway, Arkansas . The over 16,000 square ... on March 26 th 2015 and brings the ... "This facility represents another milestone in ...
(Date:3/31/2015)... 2015 Materials in Society Lecture ... June 30 2015   Elsevier , a ... services and publishing home of Materials Today , announced ... Materials in Society  Lecture Series . ... th International Conference on Materials for Advanced Technologies (ICMAT) ...
Breaking Biology Technology:MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4Slone Partners Fills Head of Sales at Optimal Medicine 2Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 2Elsevier Materials Science Council Introduces the Materials in Society Lecture Series at the International Conference on Materials for Advanced Technologies (ICMAT) 3
... / PRNewswire / -- Cognition Therapeutics Inc., a drug ... has closed on a $2.5 million Series A1 financing it ... to Investigational New Drug (IND) candidate status. The round was ... investing groups, and was syndicated with Tech Coast Angels.   ...
... new image and cell technologies have for the first ... red blood cells. The researchers, from the Walter and ... of Technology, Sydney (UTS), achieved this long-held aim using ... a technology platform new to Australia. The detailed ...
... Gen-Probe Incorporated (Nasdaq: GPRO ) announced today that ... 2010 financial results on Tuesday, February 15, 2011 at approximately ... by a conference call with management at 4:30 p.m. ET. ... and may be accessed on the investors section of the ...
Cached Biology Technology:Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 2Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimer's Disease Drug Treatment Program 3Malaria parasite caught red-handed invading blood cells 2Malaria parasite caught red-handed invading blood cells 3Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call 2
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... NEW YORK , March 17, 2015 /PRNewswire/ ... , the largest exhibition for service robots ever ... . RoboUniverse takes place on May 11-13, 2015 ... Sponsors and exhibitors for the event include: Acorn ... Motion Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... results in irreversible damage to the heart that ... results from the limited ability of the myocardium ... from Tufts University now document the existence of ... stem cells with therapeutic potency for myocardial tissue ...
... The World Health Organization (WHO) warned about increased ... dengue fever across tsunami-affected areas in Southeast Asia. ... region on 26 December, the organization is strengthening ... for mosquito vectors to multiply to sufficient levels, ...
... potentially dangerous chemical has been found by Health Canada ... processed foods, especially canned or bottled foods. A new ... student Carolina Perez Locas explains the presence of this ... The study, published in the October, 2004 issue of ...
Cached Biology News:WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 2WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 3WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas 4
...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... making flow cytometry accessible to anyone in the ... latest addition to Guavas on-demand microcapillary flow cytometry ... to use, surprisingly affordable, very compact, and nicely ... The Guava EasyCyte Mini has all of the ...
... systems provide automated, higher throughput screening of ... tubes. This flexible sample format makes the ... basic research, target validation, assay development, and ... the Guava PCA-96 uses a green laser ...
Biology Products: